英派药业-B今日盘中大涨6.95%，引起了市场的广泛关注。
消息面上，公司于5月13日以每股20.10港元定价登陆港交所，香港公开发售获2282.4倍超额认购，一手中签率仅1.5%，首日收报41.86港元，较招股价涨108.26%，上市后市场情绪延续强势。此外，公司核心产品塞纳帕利已于2025年1月获批用于卵巢癌一线维持治疗，并于2025年12月纳入国家医保目录，自今年1月起正式执行医保价格，有望推动营收持续放量。
公司在研管线IMP32为全球首个靶向CEACAM5的双载荷ADC，具备First-in-Class地位，展示了公司的研发实力和未来增长潜力，进一步增强了投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.